CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Vemurafenib +1 moredrug
Likely dose
Vemurafenib 480 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05068752
NCT05068752Phase 2Completed
CompareCT.gov

A Phase II Trial of Vemurafenib in Combination With Sorafenib to Treat Patients With Advanced KRAS Mutated Pancreatic Cancer: Targeting RAF Dimers to Suppress Oncogenic RAS Signaling (The Dr. Nate Nieto Study)

HonorHealth Research Institute·interventional·Posted Oct 6, 2021·Updated Mar 30, 2026

In Brief

A Phase 2 clinical trial evaluating Vemurafenib and Sorafenib for Pancreas Cancer. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreas Cancer
CountriesUnited States
CollaboratorsBayer, Genentech, Inc.

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedOct 6, 2021
Enrollment StartOct 28, 2021
Primary CompletionNov 8, 2024
Study CompletionDec 13, 2024
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 4.7 years ago

Interventions

Vemurafenibdrug

Vemurafenib 480 mg PO BID daily given with Sorafenib 200 mg PO BID

Sorafenibdrug

Sorafenib 200 mg PO BID and Vemurafenib 480 mg PO BID daily